首页> 外文期刊>Journal of Virology >In vitro cytotoxicity against Marek's disease lymphoblastoid cell lines after enzymatic removal of Marek's disease tumor-associated surface antigen.
【24h】

In vitro cytotoxicity against Marek's disease lymphoblastoid cell lines after enzymatic removal of Marek's disease tumor-associated surface antigen.

机译:在酶促去除MAREK疾病肿瘤相关表面抗原后,对MAREK疾病淋巴母细胞系的体外细胞毒性细胞毒性。

获取原文
获取外文期刊封面目录资料

摘要

Marek's disease tumor-associated surface antigen (MATSA) has been claimed to be the target of cytotoxic lymphocytes in in vitro tests for Marek's disease immunity. Treatment with papain, but not with trypsin or mixed glycosidases, removed MATSA from certain Marek's disease lymphoblastoid cell lines. Tumor cells with and without MATSA were used as target cells for in vitro studies on cell-mediated immune responses with sensitized spleen cells in a chromium release assay. The removal of MATSA did not influence the results of the chromium release assay. Attempts to block the cell-mediated cytotoxicity in vitro by coating tumor cells with an anti-MATSA serum failed. It was concluded that cell-mediated immune responses against Marek's disease tumor cells are directed against an as yet undefined antigen(s).
机译:MAREK的疾病肿瘤相关的表面抗原(MATSA)已被声称是在体外测试中的细胞毒性淋巴细胞的靶标,用于MAREK疾病免疫。用木瓜蛋白酶处理,但没有胰蛋白酶或混合糖苷酶,从某些马雷克病淋巴母细胞系中取出matsa。使用和不含Matma的肿瘤细胞用作靶细胞,用于对细胞介导的免疫应答在铬释放测定中具有敏化脾细胞的体外研究。去除Matsa不会影响铬释放测定的结果。试图通过用抗Matsa血清涂覆肿瘤细胞来阻断细胞介导的细胞毒性。得出结论,细胞介导针对MAREK疾病肿瘤细胞的免疫应答涉及到尚未确定的抗原。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号